ReviewCardiovascular intervention and therapeutics2023
Clinical expert consensus document on drug-coated balloon for coronary artery disease from the Japanese Association of Cardiovascular Intervention and Therapeutics.
Review in Cardiovascular intervention and therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 74 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Drug Coated Balloons Versus Drug-Eluting Stents for Severe Coronary Calcification After Optimal Calcium Modification Assessed by QFR (PRECISE CAL Study)
An Investigator-initiated, Multicenter, Open-label, Randomized Controlled Non-inferiority Trial to Assess the Single vs. Dual Antiplatelet Therapy in the Chronic Coronary Syndrome (CCS) and Stable Acute Coronary Syndrome (S-ACS) Patients Undergoing Percutaneous Intervention With Drug-coated Balloons (DCB)-Only Strategy (KONG-FREEDOM-I)
Who cites it
74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Evaluating drug-coated balloon versus drug-eluting stent for the treatment of small coronary artery disease: a meta-analysis and systematic review.Frontiers in cardiovascular medicine · 2026Pooled it
- Paclitaxel-Coated Balloons versus Drug-Eluting Stents in Small Vessel Coronary Artery Disease: A Systematic Review and Meta-Analysis.Arquivos brasileiros de cardiologia · 2025Pooled it
- Drug-coated balloons versus drug-eluting stents in patients with in-stent restenosis: An updated meta-analysis with trial sequential analysis.Journal of cardiothoracic surgery · 2024Pooled it
- CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024.Cardiovascular intervention and therapeutics · 2024Guideline
- Paclitaxel drug-coated balloon angioplasty for de novo coronary lesions in an expanded real world clinical setting: the multicenter ALLIANCE registry.Cardiovascular intervention and therapeutics · 2026Trial
- 2026 revised CVIT clinical expert consensus on drug coated balloons for coronary artery disease.Cardiovascular intervention and therapeutics · 2026Review
- Residual inflammatory risk after percutaneous coronary intervention: current insights and future perspectives.Cardiovascular intervention and therapeutics · 2026Review
- Intravascular ultrasound evaluation of novel non-compliant versus conventional semi-compliant cutting balloon for calcified coronary lesions.Cardiovascular intervention and therapeutics · 2026Observational
- Association between short (≤ 30-day) dual antiplatelet therapy and 1-year major adverse cardiac events after drug-coated balloon-based non-stent percutaneous coronary intervention following optimal lesion preparation: a propensity score-based cohort study.Cardiovascular intervention and therapeutics · 2026Article
- Arterial remodeling and plaque changes after balloon angioplasty for de novo coronary lesions using DCB.Cardiovascular intervention and therapeutics · 2026Article
- Angiographic residual stenosis and clinical outcomes after elective drug-coated balloon angioplasty for de novo coronary lesions: a single center retrospective study.Cardiovascular intervention and therapeutics · 2026Article
- Longitudinal Wire Bias Pattern on Intravascular Ultrasound as an Independent Predictor of Coronary Artery Injury During Orbital Atherectomy for Calcified Nodules: A Single-Center Retrospective Study.Circulation reports · 2026Article
- Acute coronary syndrome associated with probable immunoglobulin G4-related coronary periarteritis successfully treated with a drug-coated balloon.Journal of cardiology cases · 2026Article
- The trap device retrieves the detached stent that is floating within the ascending aorta.Journal of cardiothoracic surgery · 2026Article
- Abbreviated dual antiplatelet therapy after percutaneous coronary intervention with drug coated balloons in acute coronary syndromes: insights from the SWEDEHEART registry.European heart journal. Cardiovascular pharmacotherapy · 2026Observational
- Ostial right coronary artery lesions: what to know and how to overcome.Cardiovascular intervention and therapeutics · 2026Review
- Article
- Clinical Impact of Drug-Coated Balloon-Based Percutaneous Coronary Intervention in Coronary Artery Disease Patients With Chronic Heart Failure.Circulation reports · 2026Article
- Long-Term Efficacy of Drug-Coated Balloon Angioplasty vs. Drug-Eluting Stent for De Novo Large-Vessel Coronary Arteries.Circulation reports · 2026Article
- CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026.Cardiovascular intervention and therapeutics · 2026Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-coated balloon (DCB) technology was developed to deliver the antiproliferative drugs to the vessel wall without leaving any permanent prosthesis or durable polymers. The absence of foreign material can reduce the risk of very late stent failure, improve the ability to perform bypass-graft surgery, and reduce the need for long-term dual antiplatelet therapy, potentially reducing associated bleeding complications. The DCB technology, like the bioresorbable scaffolds, is expected to be a therapeutic approach that facilitates the "leave nothing behind" strategy. Although newer generation drug-eluting stents are the most common therapeutic strategy in modern percutaneous coronary interventions, the use of DCB is steadily increasing in Japan. Currently, the DCB is only indicated for treatment of in-stent restenosis or small vessel lesions (< 3.0 mm), but potential expansion for larger vessels (≥ 3.0 mm) may hasten its use in a wider range of lesions or patients with obstructive coronary artery disease. The task force of the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT) was convened to describe the expert consensus on DCBs. This document aims to summarize its concept, current clinical evidence, possible indications, technical considerations, and future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.